- Home
- PTLO vs GYRE Comparison
PTLO vs GYRE Comparison
Compare PTLO & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTLO
- GYRE
- Stock Information
- Founded
- PTLO 1963
- GYRE 2002
- Country
- PTLO United States
- GYRE United States
- Employees
- PTLO N/A
- GYRE N/A
- Industry
- PTLO Restaurants
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- PTLO Consumer Discretionary
- GYRE Health Care
- Exchange
- PTLO Nasdaq
- GYRE Nasdaq
- Market Cap
- PTLO 829.2M
- GYRE 897.1M
- IPO Year
- PTLO 2021
- GYRE N/A
- Fundamental
- Price
- PTLO $11.11
- GYRE $7.27
- Analyst Decision
- PTLO Buy
- GYRE
- Analyst Count
- PTLO 8
- GYRE 0
- Target Price
- PTLO $14.13
- GYRE N/A
- AVG Volume (30 Days)
- PTLO 1.8M
- GYRE 173.5K
- Earning Date
- PTLO 08-05-2025
- GYRE 08-12-2025
- Dividend Yield
- PTLO N/A
- GYRE N/A
- EPS Growth
- PTLO 8.11
- GYRE N/A
- EPS
- PTLO 0.43
- GYRE 0.02
- Revenue
- PTLO $721,160,000.00
- GYRE $100,643,000.00
- Revenue This Year
- PTLO $12.29
- GYRE $21.04
- Revenue Next Year
- PTLO $13.80
- GYRE $89.64
- P/E Ratio
- PTLO $26.26
- GYRE $90.89
- Revenue Growth
- PTLO 4.57
- GYRE N/A
- 52 Week Low
- PTLO $8.38
- GYRE $6.11
- 52 Week High
- PTLO $15.78
- GYRE $19.00
- Technical
- Relative Strength Index (RSI)
- PTLO 43.31
- GYRE 43.28
- Support Level
- PTLO $10.78
- GYRE $7.07
- Resistance Level
- PTLO $12.23
- GYRE $7.63
- Average True Range (ATR)
- PTLO 0.41
- GYRE 0.44
- MACD
- PTLO -0.08
- GYRE 0.02
- Stochastic Oscillator
- PTLO 24.53
- GYRE 33.33
About PTLO Portillo's Inc.
Portillos Inc serves the Chicago street food industry through high-energy and multichannel restaurants designed to ignite the senses and create memorable dining experiences. It owns and operates fast-casual restaurants in the United States, along with two food production commissaries in Illinois. Its menu includes hot dogs, beef and sausage sandwiches, sandwiches and ribs, salads, burgers, chicken, Barnelli's pasta, sides and soup, and desserts and shakes.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.